Japan, Oct. 5 -- WUXI BIOLOGICS IRELAND LTD has got intellectual property rights for 'GENETICALLY MODIFIED CELL LINE PRODUCING RECOMBINANT GLYCOPROTEIN HAVING MANNOSE-TERMINATED N-GLYCAN.' Other related details are as follows:
Application Number: JP,2024-203541
Category (FI): A61K38/47,A61K47/12,A61K47/26,A61K9/08,A61P43/00,105
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Nov. 5, 2024
Publication Date: March 18, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication....